Stocks
Vanda Pharmaceuticals Financial Statements (VNDA) |
||||||||||
| Vanda Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.02.2020 | 11.02.2021 | 24.02.2022 | 09.02.2023 | 08.02.2024 | 07.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 227.2 | 248.2 | 268.7 | 254.4 | 192.6 | 190.9 | |||
| Operating Income, bln rub | 22.8 | 27.2 | 42.2 | 6.33 | -14.0 | -37.5 | ||||
| EBITDA, bln rub | ? | 25.7 | 30.1 | 45.0 | 9.06 | -10.9 | -32.1 | |||
| Net profit, bln rub | ? | 115.6 | 23.3 | 33.2 | 6.28 | 2.51 | -16.4 | |||
| OCF, bln rub | ? | 45.9 | 51.8 | 64.2 | 32.0 | 12.8 | -17.7 | |||
| CAPEX, bln rub | ? | 1.02 | 1.80 | 0.552 | 0.679 | 0.383 | 0.529 | |||
| FCF, bln rub | ? | 44.9 | 50.0 | 63.7 | 31.3 | 12.4 | -18.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 179.9 | 197.6 | 200.9 | 223.8 | 191.8 | 214.9 | ||||
| Cost of production, bln rub | 24.5 | 23.4 | 25.6 | 24.3 | 14.8 | 16.0 | ||||
| R&D, bln rub | 48.6 | 55.6 | 75.4 | 85.8 | 76.8 | 78.9 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Assets, bln rub | 483.7 | 533.5 | 593.8 | 634.2 | 648.4 | 645.1 | ||||
| Net Assets, bln rub | ? | 410.9 | 453.3 | 504.9 | 527.2 | 544.9 | 541.2 | |||
| Debt, bln rub | 12.5 | 13.6 | 10.1 | 11.1 | 9.40 | 5.49 | ||||
| Cash, bln rub | 312.1 | 367.7 | 432.8 | 466.9 | 388.3 | 376.3 | ||||
| Net debt, bln rub | -299.7 | -354.1 | -422.8 | -455.7 | -378.9 | -370.8 | ||||
| Ordinary share price, rub | 16.4 | 13.1 | 15.7 | 7.39 | 4.22 | 4.47 | ||||
| Number of ordinary shares, mln | 53.1 | 54.4 | 55.5 | 56.5 | 57.4 | 58.3 | ||||
| Market cap, bln rub | 872 | 715 | 872 | 417 | 242 | 260 | ||||
| EV, bln rub | ? | 572 | 361 | 449 | -38 | -137 | -110 | |||
| Book value, bln rub | 388 | 432 | 485 | 509 | 424 | 425 | ||||
| EPS, rub | ? | 2.17 | 0.43 | 0.60 | 0.11 | 0.04 | -0.28 | |||
| FCF/share, rub | 0.85 | 0.92 | 1.15 | 0.55 | 0.22 | -0.31 | ||||
| BV/share, rub | 7.30 | 7.93 | 8.73 | 9.01 | 7.38 | 7.30 | ||||
| EBITDA margin, % | ? | 11.3% | 12.1% | 16.8% | 3.56% | -5.68% | -16.8% | |||
| Net margin, % | ? | 50.9% | 9.40% | 12.3% | 2.47% | 1.30% | -8.59% | |||
| FCF yield, % | ? | 5.15% | 6.99% | 7.30% | 7.50% | 5.13% | -6.99% | |||
| ROE, % | ? | 28.1% | 5.15% | 6.57% | 1.19% | 0.46% | -3.03% | |||
| ROA, % | ? | 23.9% | 4.37% | 5.58% | 0.99% | 0.39% | -2.54% | |||
| P/E | ? | 7.55 | 30.6 | 26.3 | 66.5 | 96.5 | -15.9 | |||
| P/FCF | 19.4 | 14.3 | 13.7 | 13.3 | 19.5 | -14.3 | ||||
| P/S | ? | 3.84 | 2.88 | 3.24 | 1.64 | 1.26 | 1.36 | |||
| P/BV | ? | 2.25 | 1.66 | 1.80 | 0.82 | 0.57 | 0.61 | |||
| EV/EBITDA | ? | 22.3 | 12.0 | 9.97 | -4.24 | 12.5 | 3.43 | |||
| Debt/EBITDA | -11.7 | -11.8 | -9.39 | -50.3 | 34.6 | 11.5 | ||||
| R&D/CAPEX, % | 4 774% | 3 096% | 13 653% | 12 632% | 20 058% | 14 921% | ||||
| CAPEX/Revenue, % | 0.45% | 0.72% | 0.21% | 0.27% | 0.20% | 0.28% | ||||
| Vanda Pharmaceuticals shareholders | ||||||||||
